Accropeutics reports positive data from phase 2 trial of AC-201, an oral, selective TYK2/JAK1 inhibitor, to treat moderate-to-severe plaque psoriasis: New York Thursday, May 22, 2 ...

Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for a Phase I trial for ASC50 for the ...

U.S. prices for newly-launched pharmaceuticals more than doubled last year compared to 2021, as companies leveraged ...

Let’s discuss four foods to avoid with psoriasis that may be affecting your skin, along with healthier substitutes.

By elevating patient perspectives from an afterthought to a core part of the process, payers can create a system that aligns ...

Pyzchiva® is a key biosimilar value driver for the Sandoz growth strategy. It has been launched in 23 markets in Europe. The autoinjector is now available in Spain and will continue to roll out across ...

Hair care expert on the smoothening treatment your scalp might secretly hate and the one that's right for your hair type.

For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers ...

A new study published in the journal of Acta Dermato Venerologica showed that menopause might have neutral to negative impact ...

Accropeutics said the Phase II trial of AC-201 will support the drugs progression to a Phase III trial in plaque psoriasis.

For patients with genital psoriasis, apremilast improved genital Physician Global Assessment scores, itch, and quality of life with a tolerable safety profile.

Treatment with guselkumab among patients with psoriasis does not contribute to the risk for or progression of liver fibrosis.